ReviewCancer science2026
Lung Cancer Brain Metastasis: Brain Microenvironmental Adaptation, Therapeutic Resistance and Translational Strategies.
Review in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lung cancer brain metastasis (LCBM) remains one of the most challenging clinical conditions limiting survival and neurological function. The development of LCBM is shaped by continuous exchange of molecular signals between tumor cells and the brain microenvironment, involving blood-brain barrier remodeling, glial and immune reprogramming, neuronal signaling, and metabolic adaptation. Together, these phenomena support brain colonization, immune escape, and therapeutic resistance. The management of LCBM has improved with the advent of stereotactic radiotherapy, targeted therapy, immunotherapy, chemoimmunotherapy, and antibody-drug conjugates. Yet durable intracranial control is still limited by intrinsic barrier heterogeneity, protected residual intracranial disease, and molecular resistance. This review summarizes recent advances in biology, preclinical modeling, therapeutic resistance, and translational treatment strategies of LCBM. By linking brain-specific metastatic biology with evolving therapeutic approaches, this review provides a framework for understanding LCBM progression and for developing more effective strategies to overcome intracranial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.